stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Book value per share
Vir Biotechnology, Inc.'s book value per share at the end of fiscal 2025 was 5.5×, down 34.6% from 8.4× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 5.3×. Over the past ten years it has ranged from −23.4× (fiscal 2018) to 15.7× (fiscal 2022); the current reading is higher than 33% of that period. Vir Biotechnology, Inc. ranks 149th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.5× | (34.57%) |
| FY2024 | 8.4× | (28.78%) |
| FY2023 | 11.9× | (24.34%) |
| FY2022 | 15.7× | 42.15% |
| FY2021 | 11.0× | 83.25% |
| FY2020 | 6.0× | (56.93%) |
| FY2019 | 14.0× | — |
| FY2018 | −23.4× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 5.3× | (9.64%) |
| Jun 2026 | 5.9× | 6.21% |
| Mar 2026 | 5.5× | (0.16%) |
| Dec 2025 | 5.5× | (3.59%) |
| 30 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| VIR Vir Biotechnology, Inc. | 5.3× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 5.1× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 4.2× |
| IMNM Immunome, Inc. compare | 4.0× |
| ZYME Zymeworks Inc. compare | 3.6× |
| REPL Replimune Group, Inc. compare | 1.9× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 1.7× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement